NORTHERN TRUST CORP - PHATHOM PHARMACEUTICALS INC ownership

PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 85 filers reported holding PHATHOM PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.01 and the average weighting 0.2%.

Quarter-by-quarter ownership
NORTHERN TRUST CORP ownership history of PHATHOM PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$2,787,207
-10.4%
268,776
+23.8%
0.00%0.0%
Q2 2023$3,110,103
+104.6%
217,186
+2.0%
0.00%
Q1 2023$1,520,114
-35.8%
212,901
+0.9%
0.00%
Q4 2022$2,367,970
+11.5%
211,049
+10.1%
0.00%
Q3 2022$2,124,000
+32.6%
191,709
+1.0%
0.00%
Q2 2022$1,602,000
-34.2%
189,888
+6.2%
0.00%
Q1 2022$2,433,000
-34.2%
178,810
-4.8%
0.00%
-100.0%
Q4 2021$3,696,000
-38.1%
187,905
+1.0%
0.00%0.0%
Q3 2021$5,973,000
-9.4%
186,076
-4.5%
0.00%0.0%
Q2 2021$6,596,000
+33.2%
194,876
+47.8%
0.00%0.0%
Q1 2021$4,952,000
+13.5%
131,856
+0.4%
0.00%0.0%
Q4 2020$4,363,000
-10.2%
131,321
-0.9%
0.00%0.0%
Q3 2020$4,857,000
+2.9%
132,448
-7.7%
0.00%0.0%
Q2 2020$4,721,000
+39.3%
143,453
+9.3%
0.00%0.0%
Q1 2020$3,389,000
-4.9%
131,258
+14.7%
0.00%0.0%
Q4 2019$3,563,000114,4260.00%
Other shareholders
PHATHOM PHARMACEUTICALS INC shareholders Q1 2023
NameSharesValueWeighting ↓
Medicxi Ventures Management (Jersey) Ltd 3,760,869$39,000,21212.45%
Frazier Life Sciences Management, L.P. 10,109,279$104,833,2236.96%
Decheng Capital Management III (Cayman), LLC 850,000$8,814,5002.94%
Carlyle Group Inc. 3,496,808$36,191,9631.57%
Ghost Tree Capital, LLC 395,000$4,096,1501.35%
Newtyn Management, LLC 500,000$5,185,0001.28%
Altium Capital Management LP 220,000$2,281,4001.19%
StepStone Group LP 422,085$4,377,0210.98%
MPM BioImpact LLC 347,332$3,601,8330.96%
NEA Management Company, LLC 1,276,595$12,238,2900.94%
View complete list of PHATHOM PHARMACEUTICALS INC shareholders